Translate this page into:
Ga-68 DOTATATE positron emission tomography/computer tomography in initial staging and therapy response evaluation in a rare case of primary neuroblastoma in neck
Address for correspondence: Dr. Bhagwant Rai Mittal, Department of Nuclear Medicine and PET, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012, India. E-mail: brmittal@yahoo.com
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Gallium-68 (Ga-68) DOTA-peptide positron emission tomography/computer tomography (PET/CT) has higher sensitivity and improved spatial resolution for the detection of somatostatin receptor expressing tumors than conventional somatostatin receptor scintigraphy. We present the findings of Ga-68 DOTATATE PET/CT in a rare case of primary neuroblastoma of the neck in a 12-year-old female child and its role in the evaluation of the treatment response.
Keywords
Extra-abdominal neuroblastoma
gallium-68 DOTATATE
positron emission tomography/computer tomography
response evaluation
INTRODUCTION
Gallium-68 (Ga-68) DOTA-peptide positron emission tomography/computer tomography (PET/CT) has a higher sensitivity and improved spatial resolution for the detection of somatostatin receptor expressing tumors than conventional somatostatin receptor scintigraphy (SRS). Anatomical evaluation of therapy response does not correlate well with progression-free survival, clinical outcome, or quality of life in neuroendocrine tumors (NET). We present Ga-68 DOTATATE PET/CT findings in a rare case of primary neuroblastoma of the neck and its role in the evaluation of the treatment response.
CASE REPORT
The case we present here is about a 12-year-old female child presented with gradual onset painless neck swelling. Contrast enhanced CT study demonstrated large soft-tissue lesions on the left side of the neck, which was later on histopathologically confirmed as neuroblastoma. Ga-68 DOTATATE PET/CT performed for initial staging showed [Figure 1a-c] abnormal tracer uptake in an enhancing large soft-tissue mass on the left side of neck (SUVmax 11.7), the left cervical and axillary lymph nodes, and bones suggestive of primary neuroblastma in the neck with nodal and skeletal metastases. The patient was treated with three cycles of chemotherapy and Ga-68 DOTATATE PET/CT study was repeated for treatment response evaluation. Post-chemotherapy Ga-68 DOTATATE PET/CT showed [Figure 2a-c] decrease in tracer uptake in the soft-tissue mass in the neck (SUVmax 5.1 in comparison to SUVmax 11.7 in the pre-therapy scan), in the cervical and axillary lymph nodes, in the paravertebral mass (SUVmax 5.5 in comparison to SUVmax 11.0 in the pre-therapy scan) and in the bones (SUVmax 3.8 in comparison to SUVmax 10.0 in the pre-therapy scan) without significant change in the size of the lesions suggesting favorable response to chemotherapy. F-18 fluoro-2-deoxy-D-glucose (FDG) PET/CT was also performed before and after chemotherapy, which confirmed favorable metabolic response, although the decrease in uptake of F-18 FDG was of lesser magnitude than decrease in Ga-68 DOTATATE uptake.
- Pre-therapy Gallium-68 (Ga-68) DOTATATE positron emission tomography/computer tomography (PET/CT) coronal image (a) showing abnormal tracer uptake in an enhancing large soft tissue mass in the left neck (SUVmax 11.7), left cervical and axillary lymph nodes, and multiple bones. Transaxial CT (b) and fused positron emission tomography/computer tomography (PET/CT) (c) images show abnormal tracer uptake in a large enhancing softtissue mass on the left side of the neck (SUVmax 11.7)
- Post-chemotherapy Ga-68 DOTATATE PET/CT coronal image (b) shows decrease in tracer uptake in the soft-tissue mass in the neck (SUVmax 5.1), cervical and axillary lymph nodes and in the skeleton without significant change in the size of the lesions. Transaxial CT, (b) and fused PET/CT (c) images show a significant decrease in tracer avidity (SUVmax 5.1) compared with pre-therapy scan
DISCUSSION
Neuroblastoma arises from primitive neuroblasts of the embryonic neural crest. They can occur anywhere within the sympathetic nervous system.[1] The primary tumors most commonly occur within the abdomen (65%) and about half of these tumors arise from the adrenal medulla. Other common sites of neuroblastoma include the neck, chest, and pelvis.[2] In general, somatostatin receptors (particularly subtype 2) are expressed in these tumors. Therefore, SRS is a useful imaging modality in patients with neuroblastoma.[345] Ga-68-DOTA-peptide PET/CT has higher sensitivity and improved spatial resolution for the detection of somatostatin receptor positive tumors than conventional SRS and is superior to Indium-111 octreotide SPECT in detecting NET.[6] Ga-68 DOTA-peptide PET is superior to I-123 MIBG imaging and even to the CT or MRI technique in pre-therapy staging of neuroblastoma.[7] In this report, we showed Ga-68-DOTATATE PET/CT findings in a patient with primary extra-abdominal neuroblastoma. The peptide receptor radionuclide therapy (PRRNT) with 177 Lu-DOTATATE is safe and feasible in children with relapsed or primary refractory high-risk neuroblastoma.[8] Ga-68 DOTATATE PET/CT study may further help in the selection of patients for PRRNT in such patients with extensive disease.[9]
Anatomical evaluation of therapy response does not correlate well with progression-free survival, clinical outcome, or quality of life in NET.[10] Previous study has shown that the decreased Ga-68 DOTATATE uptake in NET after chemotherapy can predict clinical improvement.[11] In the current case, Ga-68 DOTATATE PET/CT showed favorable metabolic response to treatment despite significant residual tumor on CT. This interesting case illustrates the utility of Ga-68 DOTATATE PET/CT in the staging and treatment response evaluation in a rare case of primary neuroblastoma of the neck.
Source of Support: Nil
Conflict of Interest: None declared
REFERENCES
- Disseminated neuroblastoma in children older than one year at diagnosis: Comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol. 2003;21:1592-601.
- [Google Scholar]
- Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth Differ. 1994;5:1-8.
- [Google Scholar]
- Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma. Pediatr Blood Cancer. 2011;56:584-9.
- [Google Scholar]
- Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe (1)-Tyr (3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42-8.
- [Google Scholar]
- Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865-73.
- [Google Scholar]
- 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52:1041-7.
- [Google Scholar]
- Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
- [Google Scholar]
- Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging. Nucl Med Commun. 2004;25:253-7.
- [Google Scholar]
- 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349-56.
- [Google Scholar]